

INFLUENZA

Pharmacy Assessment Protocol

ELIGIBILITY FOR SERVICE

The pharmacy will refer patients with the any of the following symptoms/conditions for further medical evaluation:

- Patients that are pregnant
- Immunocompromised
- Any condition requiring supplemental oxygen therapy
- Children <3 years of age
- Temperature >103° F
- Respiratory rate of >30 breaths per minute
- Oxygen saturation <90%
- Pulse > 125 beats per minute

TESTING CRITERIA

Consider testing anyone presenting with influenza-like symptoms during times of influenza activity when the result will influence clinical management and outbreak response:

Chills	Malaise	Fatigue	Nasal congestion	Vomiting	Sore throat	Vomiting
Fever	Headache	Rhinorrhea	Nonproductive cough	Diarrhea	Weakness	Abdominal pain

PRESCRIBING

Upon a positive result of a CLIA-waived test, and if symptoms have been present for <48 hours, the pharmacist shall identify any precautions or contraindications to therapy and then prescribe the most appropriate treatment.

Oral Oseltamivir Treatment*		
<u>Weight</u>	<u>Dose</u>	<u>Duration</u>
16-23 kg	45 mg BID orally	5 Days
>23-40 kg	60 mg BID orally	5 Days
Adults and Children >40 kg	75 mg BID orally	5 Days
*Dose may need to be renally adjusted		

Oral Baloxavir Marboxil Treatment		
<u>Age</u>	<u>Dose</u>	<u>Duration</u>
5 years and older <20kg	2mg/kg once	One dose
5 years and older 20 kg to <80 kg	40 mg once	One dose
5 years and older >80 kg and above	80 mg once	One dose

Zanamivir Treatment		
<u>Age</u>	<u>Dose</u>	<u>Duration</u>
7 years and older	10 mg (two 5mg inhalations) BID	5 Days

The pharmacist may also prescribe appropriate postexposure chemoprophylaxis.

CRITERIA FOR CHEMOPROPHYLAXIS

Household contacts 3 years and older who are at very high risk of complications AND are unvaccinated

Oral Oseltamivir Post-Exposure Chemoprophylaxis		
<u>Weight</u>	<u>Dose</u>	<u>Duration</u>
16-23 kg	45 mg once daily orally	7 Days
24-40 kg	60 mg once daily orally	7 Days
Adults and Children >40 kg	75 mg once daily orally	7 Days
Zanamivir Post-Exposure Chemoprophylaxis		
<u>Age</u>	<u>Dose</u>	<u>Duration</u>
7 years and older	10 mg (two 5mg inhalations) once daily	7 Days
Oral Baloxavir Marboxil Chemoprophylaxis		
<u>Age</u>	<u>Dose</u>	<u>Duration</u>
5 years and older <20kg	2mg/kg	One dose
5 years and older 40 kg to <80 kg	40 mg once	One dose
5 years and older 80 kg and above	80 mg once	One dose

FOLLOW-UP

The patient should be instructed to contact the pharmacy if symptoms do not improve within 72 hours so the pharmacist can refer the patient for further medical evaluation. If a prescription is provided, and a primary care provider is identified, the pharmacy will notify the provider of record within three business days following the patient encounter.

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza.

Influenza antiviral medications: Summary for clinicians. Centers for Disease Control and Prevention. January 12, 2026. Accessed August 5, 2026, <https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html>